Eli Lilly’s oral GLP-1 medicine Foundayo (orforglipron) was associated with significant reductions in predicted long-term risks of type 2 diabetes and cardiovascular disease, according to new analyses from the Phase 3 ATTAIN-1 trial.
The post-hoc analyses evaluated adults with obesity or overweight who also had at least one weight-related health condition. The findings were published in Diabetes, Obesity and Metabolism.
At 72 weeks, people taking Foundayo at doses of 5.5 mg, 9 mg and 17.2 mg showed estimated reductions of 45%, 50% and 57%, respectively, in their predicted 10-year risk of developing type 2 diabetes compared with placebo.
The highest 17.2 mg dose was also linked to an estimated 18% reduction in predicted 10-year cardiovascular disease risk compared with placebo.
Lilly said the results add to previous evidence showing that Foundayo can help reduce body weight and improve several cardiovascular risk factors, including blood sugar, blood pressure and cholesterol levels.
The analysis used established risk models to estimate future health risks. The type 2 diabetes risk was calculated using the Cardiometabolic Disease Staging risk engine, while cardiovascular disease risk was estimated using the BMI-based Framingham risk engine. The findings therefore represent predicted risk reductions rather than evidence that Foundayo directly prevented these diseases.
Foundayo is a once-daily oral GLP-1 receptor agonist. Unlike injectable GLP-1 medicines, the small-molecule treatment can be taken at any time of day without restrictions on food or water intake. The US Food and Drug Administration approved Foundayo in April 2026 for adults with obesity, or certain adults with overweight and weight-related medical problems.
The ATTAIN-1 study included 3,127 participants across several countries, including the US, China, India, Japan, South Korea and Spain. Participants received one of three Foundayo doses or placebo for 72 weeks.
The latest findings come shortly after Lilly reported results from its ACHIEVE-4 Phase 3 study in people with type 2 diabetes. In that trial, Foundayo showed non-inferior cardiovascular safety compared with insulin glargine while also producing improvements in blood sugar control and body weight.
Lilly is continuing to study orforglipron in other conditions, including type 2 diabetes, obstructive sleep apnea, hypertension, peripheral artery disease and osteoarthritis knee pain.
The company said the latest ATTAIN-1 findings suggest that treating obesity with Foundayo could potentially provide longer-term health benefits beyond weight loss, although further clinical research will be needed to determine its impact on actual rates of diabetes and cardiovascular events.